VANCOUVER, BC -- (MARKET WIRE) -- March 16, 2007 -- Upstream Biosciences Inc. (OTCBB: UPBS) (“Upstream” or “the Company”), an emerging leader in the field of genetic diagnostics for cancer and the prediction of drug response, has announced that the Company has converted the debenture issued by Novar Capital Corp. Under the terms of the agreement, the debenture, and all interest accrued thereunder, was convertible at the Company’s election at $1.00 per share. This conversion meets the Company’s first milestone related to the recent financing announced March 5, 2007.
